Dry Overactive Bladder - A Precursor to 'Wet Overactive Bladder'?
 
Report

Dry Overactive Bladder - A Precursor to 'Wet Overactive Bladder'?Dry Overactive Bladder - A Precursor to 'Wet Overactive Bladder'? is a marketing resource from Datamonitor, a leading provider of online data, analytic and forecasting platforms for key vertical sectors. It helps 5,000 of the world's largest companies profit from better, more timely decisions.

From:
$3800
 
Introduction

Dry Overactive Bladder (dry OAB) is considered part of the overactive bladder syndrome. However, unlike wet overactive bladder (or urge urinary incontinence), it is normally only associated with urinary urgency and frequency, and not incontinence. Even so, recent studies suggest that these symptoms bother patients, with unpredictable urges disrupting daily activities and quality of life.



Scope


  • Quantitative treatment data from 365 physicians based in US, Japan, France, Germany, Italy, Spain and UK; supported by key opinion leader comments
  • Analysis of epidemiology, presentation and referral patterns, diagnostic assessment, and treatment strategy for dry OAB
  • Influences on treatment choice and perception of current drug therapies including tolterodine, oxybutynin, darifenacin and solifenacin
  • Evaluation of unmet needs and future outlook including awareness of R&D drug pipeline


  • Highlights

    Opinion leaders often recognize the impact that urge and frequency symptoms can have on a patient, even in the absence of incontinence episodes. However, prescribing physicians in general do not all accept this readily, leading to under prescribing in this patient group.



    For many years the terms urge urinary incontinence (UUI) and dry OAB have been used to describe separate syndromes with similar symptoms differentiated by the occurrence or not of incontinence. In fact is may be more suitable to consider overactive bladder as a continuum.



    Although pharmacological therapy is used less frequently in dry OAB than in UUI, the products chosen are similar, based on their activity on urge and frequency via detrusor activity; occasionally a less effective product with lower side effects may be chosen for dry OAB as opposed to a stronger, but less well tolerated product for UUI.



    Reasons to Purchase

  • Forecast product sales by understanding key aspects of dry OAB epidemiology, diagnosis and treatment
  • Gain a better understanding of the challenges facing current and future players in the dry OAB market
  • Identify physicians key concerns in dry OAB including unmet needs and the attributes that physicians believe are desirable for future treatments
Report Details:
Publisher:
Datamonitor
Type:
Market Study - April 2006
Number of pages:
50
First Publication Date:
20/4/2006
 
 
 
Copyright © Chiltern Magazine Services Ltd | Email: admin@cmsinfo.com | Tel: +(1) 508 861 0401